[EN] N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF<br/>[FR] N-(3-HÉTÉROARYLARYL)-4-ARYLARYLCARBOXAMIDES ET ANALOGUES COMME INHIBITEURS DE LA VOIE HEDGEHOG ET LEUR UTILISATION
申请人:IMPACT THERAPEUTICS INC
公开号:WO2014012511A1
公开(公告)日:2014-01-23
Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.
N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof
申请人:IMPACT Therapeutics, Inc.
公开号:US10676468B2
公开(公告)日:2020-06-09
Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.
公开了新型 N-(3-异芳基)-4-芳基羧酰胺及其类似物,由式 I 表示:其中 C 环基、D1-D4、Q1、Q2、R5 在此定义。具有式(I)的化合物是刺猬通路抑制剂。因此,本发明的化合物可用于治疗对抑制刺猬活性有反应的临床病症,如癌症。
N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF
申请人:Impact Therapeutics, Inc.
公开号:EP2875005B1
公开(公告)日:2020-11-11
N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof
申请人:IMPACT Therapeutics, Inc.
公开号:US20150191460A1
公开(公告)日:2015-07-09
Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D
1
-D
4
, Q
1
, Q
2
, R
5
are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.